Eli Lilly risk/reward positive into Solaezumab data release, says Credit Suisse Credit Suisse sees positive risk/reward ahead of Eli Lilly's Solaezumab release on Monday. The firm sees downside risk of 5% adn upside potential of 10%, but notes shares are most likely to be flattish on the results. Shares are Outperform rated with a $54.
News For LLY From The Last 14 Days
Check below for free stories on LLY the last two weeks.
Subscribe for More Information